Systemic and stratum corneum biomarkers of severity in infant atopic dermatitis include markers of innate and T helper cell-related immunity and angiogenesis.
Biomarkers
/ analysis
Case-Control Studies
Chemokines
/ analysis
Cohort Studies
Cytokines
/ analysis
Dermatitis, Atopic
/ blood
Female
Humans
Immunity, Cellular
/ immunology
Immunity, Innate
Infant
Infant, Newborn
Male
Neovascularization, Physiologic
Permeability
Severity of Illness Index
Skin
/ immunology
T-Lymphocytes, Helper-Inducer
/ immunology
Water Loss, Insensible
/ immunology
Journal
The British journal of dermatology
ISSN: 1365-2133
Titre abrégé: Br J Dermatol
Pays: England
ID NLM: 0004041
Informations de publication
Date de publication:
03 2019
03 2019
Historique:
accepted:
18
07
2018
pubmed:
23
8
2018
medline:
25
2
2020
entrez:
23
8
2018
Statut:
ppublish
Résumé
Biomarkers of atopic dermatitis (AD) are largely lacking, especially in infant AD. Those that have been examined to date have focused mostly on serum cytokines, with few on noninvasive biomarkers in the skin. We aimed to explore biomarkers obtainable from noninvasive sampling of infant skin. We compared these with plasma biomarkers and structural and functional measures of the skin barrier. We recruited 100 infants at first presentation with AD, who were treatment naive to topical or systemic anti-inflammatory therapies, and 20 healthy children. We sampled clinically unaffected skin by tape stripping the stratum corneum (SC). Multiple cytokines and chemokines and natural moisturizing factor were measured in the SC and plasma. We recorded disease severity and skin barrier function. Nineteen SC and 12 plasma biomarkers showed significant differences between healthy and AD skin. Some biomarkers were common to both the SC and plasma, and others were compartment specific. Identified biomarkers of AD severity included T helper 2-skewed markers [interleukin (IL)-13, CCL17, CCL22, IL-5]; markers of innate activation (IL-18, IL-1α, IL1β, CXCL8) and angiogenesis (Flt-1, vascular endothelial growth factor); and others (soluble intercellular adhesion molecule-1, soluble vascular cell adhesion molecule-1, IL-16, IL-17A). We identified clinically relevant biomarkers of AD, including novel markers, easily sampled and typed in infants. These markers may provide objective assessment of disease severity and suggest new therapeutic targets, or response measurement targets for AD. Future studies will be required to determine whether these biomarkers, seen in very early AD, can predict disease outcomes or comorbidities.
Sections du résumé
BACKGROUND
Biomarkers of atopic dermatitis (AD) are largely lacking, especially in infant AD. Those that have been examined to date have focused mostly on serum cytokines, with few on noninvasive biomarkers in the skin.
OBJECTIVES
We aimed to explore biomarkers obtainable from noninvasive sampling of infant skin. We compared these with plasma biomarkers and structural and functional measures of the skin barrier.
METHODS
We recruited 100 infants at first presentation with AD, who were treatment naive to topical or systemic anti-inflammatory therapies, and 20 healthy children. We sampled clinically unaffected skin by tape stripping the stratum corneum (SC). Multiple cytokines and chemokines and natural moisturizing factor were measured in the SC and plasma. We recorded disease severity and skin barrier function.
RESULTS
Nineteen SC and 12 plasma biomarkers showed significant differences between healthy and AD skin. Some biomarkers were common to both the SC and plasma, and others were compartment specific. Identified biomarkers of AD severity included T helper 2-skewed markers [interleukin (IL)-13, CCL17, CCL22, IL-5]; markers of innate activation (IL-18, IL-1α, IL1β, CXCL8) and angiogenesis (Flt-1, vascular endothelial growth factor); and others (soluble intercellular adhesion molecule-1, soluble vascular cell adhesion molecule-1, IL-16, IL-17A).
CONCLUSIONS
We identified clinically relevant biomarkers of AD, including novel markers, easily sampled and typed in infants. These markers may provide objective assessment of disease severity and suggest new therapeutic targets, or response measurement targets for AD. Future studies will be required to determine whether these biomarkers, seen in very early AD, can predict disease outcomes or comorbidities.
Identifiants
pubmed: 30132823
doi: 10.1111/bjd.17088
pmc: PMC6446820
doi:
Substances chimiques
Biomarkers
0
Chemokines
0
Cytokines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
586-596Subventions
Organisme : National Centre for the Replacement, Refinement and Reduction of Animals in Research
ID : NC/P00217X/1
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 092530/Z/10/Z
Pays : United Kingdom
Organisme : Wellcome Trust Strategic Award
ID : 098439/Z/12/Z
Pays : International
Organisme : Wellcome Trust
ID : 090066/B/09/Z
Pays : United Kingdom
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2018 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.
Références
J Allergy Clin Immunol. 2011 Apr;127(4):954-64.e1-4
pubmed: 21388663
Acta Dermatovenerol Croat. 2016 Dec;24(4):268-273
pubmed: 28128077
J Invest Dermatol. 2007 Jun;127(6):1282-4
pubmed: 17502856
Curr Opin Allergy Clin Immunol. 2015 Oct;15(5):453-60
pubmed: 26226355
J Allergy Clin Immunol. 2017 Apr;139(4S):S65-S76
pubmed: 28390479
J Invest Dermatol. 2000 Oct;115(4):640-6
pubmed: 10998136
J Clin Invest. 1999 Oct;104(8):1097-105
pubmed: 10525048
J Allergy Clin Immunol. 2017 Sep;140(3):730-737
pubmed: 28412391
Pediatr Allergy Immunol. 2003 Aug;14(4):296-301
pubmed: 12911508
Curr Opin Allergy Clin Immunol. 2016 Oct;16(5):469-76
pubmed: 27490125
Nature. 2010 Apr 29;464(7293):1367-70
pubmed: 20200518
J Allergy Clin Immunol. 2002 Jan;109(1):82-8
pubmed: 11799370
Allergy Asthma Proc. 2004 May-Jun;25(3):181-4
pubmed: 15317323
Rev Infect Dis. 1990 Jan-Feb;12(1):41-62
pubmed: 2405468
Immunol Rev. 2008 Jun;223:20-38
pubmed: 18613828
J Invest Dermatol. 2014 Aug;134(8):2071-2074
pubmed: 25029321
J Allergy Clin Immunol. 2018 Apr;141(4):1482-1485.e16
pubmed: 29233739
J Allergy Clin Immunol. 2014 Jul;134(1):82-91
pubmed: 24880632
J Allergy Clin Immunol. 2016 Dec;138(6):1639-1651
pubmed: 27671162
Curr Opin Immunol. 2006 Dec;18(6):718-26
pubmed: 17029937
J Allergy Clin Immunol. 2014 Oct;134(4):769-79
pubmed: 25282559
Curr Allergy Asthma Rep. 2014 Apr;14(4):423
pubmed: 24510535
Int Immunol. 1999 Jan;11(1):81-8
pubmed: 10050676
Cytokine. 2015 Sep;75(1):68-78
pubmed: 26070934
Arch Dermatol Res. 2006 Mar;297(9):425-9
pubmed: 16456664
Allergy. 2014 Oct;69(10):1275-9
pubmed: 24965386
Nat Immunol. 2016 Jun 21;17(7):765-74
pubmed: 27328006
Clin Exp Dermatol. 2004 May;29(3):293-6
pubmed: 15115514
Nature. 1989 May 4;339(6219):64-7
pubmed: 2469965
J Allergy Clin Immunol. 2012 Dec;130(6):1344-54
pubmed: 22951056
Br J Dermatol. 2008 Nov;159(5):1092-102
pubmed: 18684158
J Eur Acad Dermatol Venereol. 2011 Mar;25(3):334-9
pubmed: 21294778
J Allergy Clin Immunol. 2016 Oct;138(4):1233-1236
pubmed: 27474122
J Allergy Clin Immunol. 2002 Jul;110(1):139-46
pubmed: 12110833
J Immunol. 2017 Jul 15;199(2):707-717
pubmed: 28615416
J Allergy Clin Immunol Pract. 2014 Jul-Aug;2(4):371-9; quiz 380-1
pubmed: 25017523
Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11340-5
pubmed: 12151598
J Clin Diagn Res. 2015 Apr;9(4):WC01-5
pubmed: 26023628
Int Arch Allergy Immunol. 2013;160(1):63-74
pubmed: 22948248
Nat Immunol. 2011 Dec 04;13(1):58-66
pubmed: 22138715
J Eur Acad Dermatol Venereol. 2015 Nov;29(11):2136-44
pubmed: 25980674
Br J Dermatol. 2011 Mar;164(3):560-7
pubmed: 21087228
J Allergy Clin Immunol. 2016 Aug;138(2):336-49
pubmed: 27497276
Int J Mol Sci. 2016 Jul 30;17(8):
pubmed: 27483258
N Engl J Med. 2008 Apr 3;358(14):1483-94
pubmed: 18385500
Lancet. 2016 Mar 12;387(10023):1109-1122
pubmed: 26377142
Proc Natl Acad Sci U S A. 2010 Jun 22;107(25):11489-94
pubmed: 20534524
Curr Probl Dermatol. 2011;41:136-148
pubmed: 21576954
Allergy. 2016 May;71(5):588-92
pubmed: 27023268
Int Arch Allergy Immunol. 2001 Jul;125(3):236-40
pubmed: 11490156
Pediatr Allergy Immunol. 2015 Nov;26(7):634-40
pubmed: 26102348
Blood. 2011 Apr 28;117(17):4667-78
pubmed: 21364190
J Allergy Clin Immunol. 1996 Mar;97(3):828-37
pubmed: 8613640
Pediatr Allergy Immunol. 2009 Nov;20(7):633-41
pubmed: 19236603
J Am Acad Dermatol. 2015 Jul;73(1):144-53
pubmed: 25922287
J Allergy Clin Immunol. 2014 Jun;133(6):1615-25.e1
pubmed: 24655575
Cytokine. 2017 Oct;98:59-70
pubmed: 28863833
Pediatr Allergy Immunol. 2008 Nov;19(7):605-13
pubmed: 18266834
J Allergy Clin Immunol. 2008 Apr;121(4):947-54.e15
pubmed: 18155278
Clin Dermatol. 2017 Jul - Aug;35(4):349-353
pubmed: 28709564
J Allergy Clin Immunol. 2015 Oct;136(4):941-951.e3
pubmed: 26242300
Nat Genet. 2006 Apr;38(4):441-6
pubmed: 16550169
J Clin Invest. 1994 Aug;94(2):870-6
pubmed: 8040343
Dermatology. 1993;186(1):23-31
pubmed: 8435513